Advertisement
Climate change
Opinion
The View
Laurent Ramsey

Companies need to target net zero on biodiversity loss, not just climate change

  • Given the intimate relationship between climate and the biosphere, the two crises can only be tackled together
  • The private sector’s role should not be limited to risk mitigation and transparent reporting – capital expenditure can be redirected to repair damage to the ecosystem

4-MIN READ4-MIN
2
Indigeneous Fynbos flowers grow at the African National Biodiversity Institute’s Kirstenbosch Botanical Garden, in Cape Town, South Africa, on October 24. The pharmaceutical industry uses as many as 70,000 different species of plants, but unchecked development and economic expansion have led to biosphere degradation that could do serious harm to planetary and human health. Photo: EPA-EFE
Laurent Ramsey has been a managing partner of the Pictet Group since 2016.

Human health has been dependent on nature for centuries. The people of ancient Mesopotamia used hundreds of plants to treat injuries and illnesses.

Many such nature-based treatments remain in use today. By some estimates, more than a third of modern drugs are derived from flora and fauna and the pharmaceutical industry uses as many as 70,000 different species of plants.

When nature thrives, humans are healthier, too. Unfortunately, the opposite is also true.
Thanks to biodiversity degradation caused by rapid economic development, the world is already losing one potentially critical pharmaceutical remedy every two years. For example, a species of Himalayan yew tree that is used to produce Taxol, a chemotherapy drug to treat cancer, is on the brink of extinction from overharvesting and collection for fuel.
Select Voice
Select Speed
1x
AI-generated voice